Editas Medicine (EDIT) Efficacy Raises The Bigger Question - Stifel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. HNGE
8. INSP
9. MRVL
10. MTCH

Go back to Editas Medicine (EDIT) Efficacy Raises The Bigger Question - Stifel

Editas Medicine (EDIT) PT Lowered to $46 at Stifel

September 30, 2021 8:30 AM EDT

Stifel analyst Dae Gon Ha lowered the price target on Editas Medicine (NASDAQ: EDIT) to $46.00 (from $65.00) while maintaining a Hold rating.

The analyst commented, "Having digested today's BRILLIANCE data (Leber's congenital amaurosis type 10 [LCA10]) - see our take HERE - we... More

Editas Medicine (EDIT) Declines 12.5% Following Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

September 29, 2021 9:06 AM EDT

Editas Medicine (NASDAQ: EDIT) Declines 12.5% Following Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

... More

Editas Medicine (EDIT) Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

September 29, 2021 9:01 AM EDT

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced positive initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101. EDIT-101 is under development for the treatment of blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. The data, including preliminary patient safety and efficacy assessments relating to potential clinical benefits, are being presented today in an oral presentation at the XIXth International Symposium on Retinal Degeneration (RD2021) by Dr. Mark Pennesi, M.D., Ph.D.

The preliminary results... More